



## **TCR<sup>2</sup> Therapeutics to Present at the Piper Sandler Healthcare Conference**

November 23, 2022

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR<sup>2</sup> Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.

A live webcast of the presentation will be available on the Investors page of the Company's website at [investors.tcr2.com](https://investors.tcr2.com). An archived replay will be available for at least 30 days following the presentation.

### **About TCR<sup>2</sup> Therapeutics**

TCR<sup>2</sup> Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The Company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC<sup>®</sup>-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR<sup>2</sup>, please visit [www.tcr2.com](https://www.tcr2.com).

### **Investor and Media Contact:**

Carl Mauch  
Senior Director, Investor Relations and Corporate Communications  
(617) 949-5667  
[carl.mauch@tcr2.com](mailto:carl.mauch@tcr2.com)



Source: TCR<sup>2</sup> Therapeutics